|
CA2640476A1
(en)
*
|
2006-02-03 |
2007-08-16 |
Eli Lilly And Company |
Compounds and methods for modulating fx-receptors
|
|
CL2007003035A1
(es)
*
|
2006-10-24 |
2008-05-16 |
Smithkline Beechman Corp |
Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
|
|
US7902201B2
(en)
|
2007-12-04 |
2011-03-08 |
Hoffmann-La Roche Inc. |
Isoxazolo-pyrazine derivatives
|
|
WO2009071464A1
(en)
|
2007-12-04 |
2009-06-11 |
F. Hoffmann-La Roche Ag |
Isoxazolo-pyrazine derivatives
|
|
US7943619B2
(en)
|
2007-12-04 |
2011-05-17 |
Hoffmann-La Roche Inc. |
Isoxazolo-pyridazine derivatives
|
|
WO2010062861A2
(en)
*
|
2008-11-26 |
2010-06-03 |
Satiogen Pharmaceuticals, Inc. |
Bile acid recycling inhibitors for treatment of obesity and diabetes
|
|
TW201033201A
(en)
|
2009-02-19 |
2010-09-16 |
Hoffmann La Roche |
Isoxazole-isoxazole and isoxazole-isothiazole derivatives
|
|
US8389550B2
(en)
|
2009-02-25 |
2013-03-05 |
Hoffmann-La Roche Inc. |
Isoxazoles / O-pyridines with ethyl and ethenyl linker
|
|
US8222246B2
(en)
|
2009-04-02 |
2012-07-17 |
Hoffmann-La Roche Inc. |
Substituted isoxazoles
|
|
US8227461B2
(en)
|
2009-04-30 |
2012-07-24 |
Hoffmann-La Roche Inc. |
Isoxazoles
|
|
EP2427458B1
(en)
|
2009-05-05 |
2014-05-07 |
F.Hoffmann-La Roche Ag |
Isoxazole-pyridazine derivatives
|
|
WO2010127976A1
(en)
|
2009-05-05 |
2010-11-11 |
F. Hoffmann-La Roche Ag |
Isoxazole-pyridine derivatives
|
|
AU2010244552A1
(en)
|
2009-05-05 |
2011-09-29 |
F. Hoffmann-La Roche Ag |
Isoxazole-pyrazole derivatives
|
|
MX2011011490A
(es)
|
2009-05-05 |
2011-11-18 |
Hoffmann La Roche |
Derivados de isoxazol-tiazol como agonistas inversos del receptor de acido gamma-aminobutirico a (gaba a), para usarse en el tratamiento de trastornos cognitivos.
|
|
MX2011011484A
(es)
|
2009-05-07 |
2011-11-18 |
Hoffmann La Roche |
Derivados de isoxazol-piridina como moduladores del acido gamma-aminobutirico.
|
|
EP2289883A1
(en)
|
2009-08-19 |
2011-03-02 |
Phenex Pharmaceuticals AG |
Novel FXR (NR1H4) binding and activity modulating compounds
|
|
ES2552657T3
(es)
|
2010-05-26 |
2015-12-01 |
Satiogen Pharmaceuticals, Inc. |
Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
|
|
EP2545964A1
(en)
|
2011-07-13 |
2013-01-16 |
Phenex Pharmaceuticals AG |
Novel FXR (NR1H4) binding and activity modulating compounds
|
|
WO2013037482A1
(en)
|
2011-09-15 |
2013-03-21 |
Phenex Pharmaceuticals Ag |
Farnesoid x receptor agonists for cancer treatment and prevention
|
|
US8785435B2
(en)
|
2011-10-20 |
2014-07-22 |
Hoffmann-La Roche Inc. |
Solid forms
|
|
AU2012328526B2
(en)
|
2011-10-28 |
2017-05-25 |
Shire Human Genetic Therapies, Inc. |
Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
|
|
US20130108573A1
(en)
|
2011-10-28 |
2013-05-02 |
Lumena Pharmaceuticals, Inc. |
Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease
|
|
CA2907230A1
(en)
|
2013-03-15 |
2014-09-18 |
Lumena Pharmaceuticals, Inc. |
Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
|
|
AU2014229050A1
(en)
|
2013-03-15 |
2015-10-22 |
Lumena Pharmaceuticals Llc |
Bile acid recycling inhibitors for treatment of Barrett's esophagus and gastroesophageal reflux disease
|
|
SI3043865T1
(sl)
|
2013-09-11 |
2021-04-30 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Metode in farmacevtski sestavki za zdravljenje virusne okužbe s hepatitisom B
|
|
EP3071561B1
(en)
|
2013-11-22 |
2021-03-24 |
Sabre Therapeutics LLC |
Autotaxin inhibitor compounds
|
|
CN104045635A
(zh)
*
|
2014-06-23 |
2014-09-17 |
华东理工大学 |
3,4,5-三取代异恶唑类化合物及其用途
|
|
EP3006939A1
(en)
|
2014-10-06 |
2016-04-13 |
Gilead Sciences, Inc. |
Histidine-rich Glycoprotein as a marker for hepatic Farnesoid X receptor activation
|
|
US10208081B2
(en)
|
2014-11-26 |
2019-02-19 |
Enanta Pharmaceuticals, Inc. |
Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
|
|
EP3034501A1
(en)
|
2014-12-17 |
2016-06-22 |
Gilead Sciences, Inc. |
Hydroxy containing FXR (NR1H4) modulating compounds
|
|
EP3034499A1
(en)
|
2014-12-17 |
2016-06-22 |
Gilead Sciences, Inc. |
Novel FXR (NR1H4) modulating compounds
|
|
TWI698430B
(zh)
|
2015-02-13 |
2020-07-11 |
南北兄弟藥業投資有限公司 |
三環化合物及其在藥物中的應用
|
|
CA2981503C
(en)
|
2015-03-31 |
2023-09-19 |
Enanta Pharmaceuticals, Inc. |
Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
|
|
CR20170456A
(es)
|
2015-04-07 |
2018-06-13 |
Intercept Pharmaceuticals Inc |
Composiciones farmacéuticas para terapias combinadas
|
|
CA2986759C
(en)
*
|
2015-05-27 |
2025-06-17 |
Sabre Therapeutics Llc |
AUTOTAXIN INHIBITORS AND THEIR USES
|
|
WO2017133521A1
(zh)
*
|
2016-02-01 |
2017-08-10 |
山东轩竹医药科技有限公司 |
Fxr受体激动剂
|
|
US10080741B2
(en)
|
2016-04-26 |
2018-09-25 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as FXR agonists and methods of use thereof
|
|
WO2017189651A1
(en)
|
2016-04-26 |
2017-11-02 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
|
WO2017189663A1
(en)
*
|
2016-04-26 |
2017-11-02 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
|
WO2017201155A1
(en)
|
2016-05-18 |
2017-11-23 |
Enanta Pharmaceuticals, Inc. |
lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
|
|
WO2017201152A1
(en)
|
2016-05-18 |
2017-11-23 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
|
US10144729B2
(en)
|
2016-05-18 |
2018-12-04 |
Enanta Pharmaceuticals, Inc. |
Isoxazole analogs as FXR agonists and methods of use thereof
|
|
BR112018073460A2
(pt)
*
|
2016-05-25 |
2019-07-09 |
Akarna Therapeutics Ltd |
terapias combinadas usando moduladores do receptor farnesoide x (fxr)
|
|
US10772813B2
(en)
|
2016-06-03 |
2020-09-15 |
Colradel, LLC |
Compositions and methods of administering a colchicine based topical composition for the prevention of radiation fibrosis
|
|
CA2968836C
(en)
|
2016-06-13 |
2025-09-02 |
Gilead Sciences, Inc. |
FXR MODULATING COMPOUNDS (NR1H4)
|
|
NZ748641A
(en)
|
2016-06-13 |
2020-04-24 |
Gilead Sciences Inc |
Fxr (nr1h4) modulating compounds
|
|
TW201808283A
(zh)
|
2016-08-05 |
2018-03-16 |
廣東東陽光藥業有限公司 |
含氮三環化合物及其在藥物中的應用
|
|
MX2019003790A
(es)
|
2016-10-04 |
2019-09-26 |
Enanta Pharm Inc |
Analogos de isoxazol como agonistas de fxr y metodos de uso de los mismos.
|
|
WO2018081285A1
(en)
|
2016-10-26 |
2018-05-03 |
Enanta Pharmaceuticals, Inc. |
Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof
|
|
SI4122464T1
(sl)
|
2017-03-28 |
2024-07-31 |
Gilead Sciences, Inc. |
Terapevtske kombinacije za zdravljenje bolezni jeter
|
|
WO2018178260A1
(en)
|
2017-03-30 |
2018-10-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses
|
|
MX394743B
(es)
|
2017-04-12 |
2025-03-04 |
Il Dong Pharma |
Derivados de isoxazol como agonistas del receptor nuclear y usos de los mismos
|
|
CN111630051B
(zh)
|
2017-11-01 |
2023-12-26 |
百时美施贵宝公司 |
作为法尼醇x受体调节剂的烯烃螺环化合物
|
|
CA3081424A1
(en)
|
2017-11-01 |
2019-05-09 |
Bristol-Myers Squibb Company |
Spirocyclic compounds as farnesoid x receptor modulators
|
|
JP7264906B2
(ja)
|
2017-11-01 |
2023-04-25 |
ブリストル－マイヤーズ スクイブ カンパニー |
ファルネソイドｘ受容体モジュレーターとしてのアルケン化合物
|
|
PE20201170A1
(es)
|
2017-11-01 |
2020-10-28 |
Bristol Myers Squibb Co |
Compuestos biciclicos en puente como moduladores del receptor farnesoide x
|
|
CN111278817B
(zh)
|
2017-11-01 |
2023-05-16 |
百时美施贵宝公司 |
作为法尼醇x受体调节剂的多环化合物
|
|
US10689391B2
(en)
|
2017-12-12 |
2020-06-23 |
Enanta Pharmaceuticals, Inc. |
Isoxazole analogs as FXR agonists and methods of use thereof
|
|
CN110128432B
(zh)
|
2018-02-02 |
2021-03-02 |
广东东阳光药业有限公司 |
含氮三环化合物及其在药物中的应用
|
|
WO2019160813A1
(en)
|
2018-02-14 |
2019-08-22 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
|
PT3911647T
(pt)
|
2019-01-15 |
2024-03-04 |
Gilead Sciences Inc |
Composto de isoxazole como agonista de fxr e composições farmacêuticas que o contenham
|
|
EP3923943B1
(en)
|
2019-02-12 |
2024-07-31 |
Mirum Pharmaceuticals, Inc. |
Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency
|
|
CN113677659B
(zh)
|
2019-02-15 |
2024-09-06 |
百时美施贵宝公司 |
可用作类法尼醇x受体调节剂的经取代的酰胺化合物
|
|
CN113677666A
(zh)
|
2019-02-15 |
2021-11-19 |
百时美施贵宝公司 |
作为类法尼醇x受体调节剂的经取代的双环化合物
|
|
AR118050A1
(es)
|
2019-02-15 |
2021-09-15 |
Bristol Myers Squibb Co |
Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x
|
|
KR20210129684A
(ko)
|
2019-02-15 |
2021-10-28 |
브리스톨-마이어스 스큅 컴퍼니 |
파르네소이드 x 수용체 조정제로서 유용한 치환된 아미드 화합물
|
|
JP2022519906A
(ja)
|
2019-02-19 |
2022-03-25 |
ギリアード サイエンシーズ， インコーポレイテッド |
Ｆｘｒアゴニストの固体形態
|
|
WO2020231917A1
(en)
|
2019-05-13 |
2020-11-19 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
|
EP3999101A1
(en)
|
2019-07-18 |
2022-05-25 |
ENYO Pharma |
Method for decreasing adverse-effects of interferon
|
|
WO2021108974A1
(en)
|
2019-12-03 |
2021-06-10 |
Gannex Pharma Co., Ltd |
Compounds for modulating activity of fxr and uses thereof
|
|
WO2021144330A1
(en)
|
2020-01-15 |
2021-07-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of fxr agonists for treating an infection by hepatitis d virus
|
|
KR20230154806A
(ko)
|
2021-01-14 |
2023-11-09 |
엔요 파마 |
Hbv 감염 치료를 위한 fxr 작용제 및 ifn의 상승작용효과
|
|
CN117320722A
(zh)
|
2021-04-28 |
2023-12-29 |
埃尼奥制药公司 |
使用fxr激动剂作为联合治疗强烈增强tlr3激动剂的作用
|